Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy.
Esophageal Adenocarcinoma|Esophageal Cancer|HER-2 Protein Overexpression|Gastroesophageal-junction Cancer
DRUG: Nivolumab|DRUG: Trastuzumab deruxtecan
Safety of the addition of adjuvant trastuzumab deruxtecan with nivolumab for patients with esophagogastric cancer who have completed trimodality treatment, Measured by the rates of clinically significant treatment-related grade â‰¥3 adverse events or pneumonitis., First dose of study treatment, through 30-days post last dose of drug, approximately 13 months
Disease-free survival with adjuvant trastuzumab deruxtecan & nivolumab after completion of trimodality treatment for HER2+ esophageal cancer., Participants alive without disease recurrence are censored at date of last disease evaluation., First dose of study treatment until time of cancer recurrence or death from any cause, whichever occurs first, maximum of 36 months
This is an open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esophagogastric adenocarcinoma who have completed chemoradiation followed by esophagectomy. All patients will receive trastuzumab deruxtecan, 6.4 mg/kg IV, and nivolumab, 360 mg IV, every 21 days, for 17 doses over 1 year.